194 related articles for article (PubMed ID: 30944260)
1. Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.
Kellner J; Wallace C; Liu B; Li Z
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944260
[TBL] [Abstract][Full Text] [Related]
2. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
[TBL] [Abstract][Full Text] [Related]
3. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival.
Reghunathan R; Bi C; Liu SC; Loong KT; Chung TH; Huang G; Chng WJ
Oncotarget; 2013 Aug; 4(8):1230-40. PubMed ID: 23985559
[TBL] [Abstract][Full Text] [Related]
4. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
5. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
6. Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Harnoss JM; Le Thomas A; Shemorry A; Marsters SA; Lawrence DA; Lu M; Chen YA; Qing J; Totpal K; Kan D; Segal E; Merchant M; Reichelt M; Ackerly Wallweber H; Wang W; Clark K; Kaufman S; Beresini MH; Laing ST; Sandoval W; Lorenzo M; Wu J; Ly J; De Bruyn T; Heidersbach A; Haley B; Gogineni A; Weimer RM; Lee D; Braun MG; Rudolph J; VanWyngarden MJ; Sherbenou DW; Gomez-Bougie P; Amiot M; Acosta-Alvear D; Walter P; Ashkenazi A
Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16420-16429. PubMed ID: 31371506
[TBL] [Abstract][Full Text] [Related]
7. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.
Paíno T; Ocio EM; Paiva B; San-Segundo L; Garayoa M; Gutiérrez NC; Sarasquete ME; Pandiella A; Orfao A; San Miguel JF
Haematologica; 2012 Jul; 97(7):1110-4. PubMed ID: 22315496
[TBL] [Abstract][Full Text] [Related]
8. [Multiple myeloma stem cell].
Hosen N
Nihon Rinsho; 2015 Jan; 73(1):47-51. PubMed ID: 25626303
[TBL] [Abstract][Full Text] [Related]
9. The myeloma stem cell concept, revisited: from phenomenology to operational terms.
Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K
Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712
[TBL] [Abstract][Full Text] [Related]
10. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.
Hajek R; Okubote SA; Svachova H
Br J Haematol; 2013 Dec; 163(5):551-64. PubMed ID: 24111932
[TBL] [Abstract][Full Text] [Related]
11. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the B-cell compartment in plasma cell leukemia and multiple myeloma: immunoglobulin gene rearrangement of EBV-infected B-cell lines.
Commes T; Clofent G; Ghanem N; Zhang XG; Lefranc MP; Bataille R; Klein B
Leukemia; 1993 Apr; 7(4):609-17. PubMed ID: 7681918
[TBL] [Abstract][Full Text] [Related]
13. Gm40600 suppressed SP 2/0 isograft tumor by reducing Blimp1 and Xbp1 proteins.
Fang Y; Xu R; Zhai B; Hou C; Ma N; Wang L; Han G; Jiang Z; Wang R
BMC Cancer; 2019 Jul; 19(1):700. PubMed ID: 31311517
[TBL] [Abstract][Full Text] [Related]
14. [Molecular mechanism of oncogenesis and progression in human myeloma].
Kawano MM; Otsuyama K
Nihon Rinsho; 2007 Dec; 65(12):2187-93. PubMed ID: 18069259
[TBL] [Abstract][Full Text] [Related]
15. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
[TBL] [Abstract][Full Text] [Related]
16. The search for multiple myeloma stem cells: the long and winding road.
Basak GW; Carrier E
Biol Blood Marrow Transplant; 2010 May; 16(5):587-94. PubMed ID: 19895894
[TBL] [Abstract][Full Text] [Related]
17. [Emergence of cancer stem cells or tumor-initiating/propagating cells and relapse in multiple myeloma].
Cahu J; Sola B
Bull Cancer; 2014 Dec; 101(12):1074-9. PubMed ID: 25467977
[No Abstract] [Full Text] [Related]
18. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
19. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
